AbCellera Biologics Inc [NASDAQ: ABCL] gained 16.67% or 0.45 points to close at $3.15 with a heavy trading volume of 7614049 shares.
The daily chart for ABCL points out that the company has recorded -18.18% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 1.96M shares, ABCL reached to a volume of 7614049 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbCellera Biologics Inc [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $12.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for AbCellera Biologics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 20, 2024. The new note on the price target was released on February 22, 2024, representing the official price target for AbCellera Biologics Inc stock. Previously, the target price had yet another raise to $6, while KeyBanc Capital Markets analysts kept a Overweight rating on ABCL stock.
The Average True Range (ATR) for AbCellera Biologics Inc is set at 0.18, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 28.02. The Price to Book ratio for the last quarter was 0.86, with the Price to Cash per share for the same quarter was set at 2.28.
Trading performance analysis for ABCL stock
AbCellera Biologics Inc [ABCL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.00. With this latest performance, ABCL shares gained by 21.62% in over the last four-week period, additionally sinking by -18.18% over the last 6 months – not to mention a drop of -22.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 66.02, with the RSI for the last a single of trading hit 70.65, and the three-weeks RSI is set at 62.40 for AbCellera Biologics Inc [ABCL]. The present Moving Average for the last 50 days of trading for this stock 2.65, while it was recorded at 2.81 for the last single week of trading, and 3.54 for the last 200 days.
AbCellera Biologics Inc [ABCL]: A deeper dive into fundamental analysis
AbCellera Biologics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.34 and a Current Ratio set at 9.34.
AbCellera Biologics Inc [ABCL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, AbCellera Biologics Inc posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc go to 10.00%.
An analysis of Institutional ownership at AbCellera Biologics Inc [ABCL]
There are presently around $38.03%, or 52.81%% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: BAKER BROS. ADVISORS LP with ownership of 27.53 million shares, which is approximately 9.4033%. BAILLIE GIFFORD & CO, holding 21.91 million shares of the stock with an approximate value of $$64.86 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $$31.47 million in ABCL stock with ownership which is approximately 3.6322%.
